Clinical Trial Update: A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and efficacy of emapalumab (anti-IFN-gamma) in patients with systemic juvenile idiopathic arthritis or adult-onset Still's disea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arthritis Juvenile
• Lymphohistiocytosis Hemophagocytic
• Macrophage Activation Syndrome
• Onset Still Disease

Drugs mentioned

• Emapalumab (emapalumab)

Snippet

Sponsor: Swedish Orphan Biovitrum | Conditions: Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic | Phase 2 | Status: COMPLETED | Results posted: 2022-01-26